| Title |
Treatment of hepatitis C virus infection in the future
|
|---|---|
| Published in |
Clinical and Translational Medicine, April 2013
|
| DOI | 10.1186/2001-1326-2-9 |
| Pubmed ID | |
| Authors |
Tatsuo Kanda, Osamu Yokosuka, Masao Omata |
| Abstract |
Two direct-acting antivirals (DAAs) against hepatitis C virus (HCV): telaprevir and boceprevir, are now available in combination with peginterferon plus ribavirin for the treatment of chronic hepatitis C infection. Although these drugs are potent inhibitors of HCV replication, they occasionally result in severe adverse events. In the present clinical trials, in their stead, several second-generation DAAs are being investigated. Most of them are being viewed with high expectations, but they also require the combination with peginterferon plus ribavirin. In the near future, we might be using all-oral DAAs and interferon-free regimens for the treatment of HCV-infected patients, and these would be potent inhibitors of HCV and have less adverse events. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 21% |
| Researcher | 5 | 17% |
| Student > Bachelor | 4 | 14% |
| Other | 4 | 14% |
| Student > Ph. D. Student | 3 | 10% |
| Other | 6 | 21% |
| Unknown | 1 | 3% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 28% |
| Agricultural and Biological Sciences | 7 | 24% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 14% |
| Chemistry | 3 | 10% |
| Biochemistry, Genetics and Molecular Biology | 2 | 7% |
| Other | 4 | 14% |
| Unknown | 1 | 3% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 December 2013.
All research outputs
#4,276,759
of 25,371,288 outputs
Outputs from Clinical and Translational Medicine
#182
of 1,060 outputs
Outputs of similar age
#35,163
of 212,360 outputs
Outputs of similar age from Clinical and Translational Medicine
#2
of 5 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,060 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,360 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.